GSK plans to spin off Consumer Healthcare unit
The demerger is scheduled to occur mid-next year. Before the separation, GSK is set to obtain a dividend of up to £8bn from Consumer Healthcare. With a portfolio
Arrowhead Pharmaceuticals has signed a global collaboration and license agreement with Horizon Therapeutics for the development of RNA interference (RNAi) therapeutic, ARO-XDH. ARO-XDH is a discovery-stage investigational RNAi